Directorate Change

RNS Number : 6108G

Mediclinic International plc

24 July 2019

 

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", or the "Company" or the "Group")

24 July 2019

DIRECTORATE CHANGES

DR EDWIN HERTZOG: INTENTION TO RETIRE AS CHAIRMAN

Mediclinic announces that Dr Edwin Hertzog, 69, has indicated his intention to retire as Chairman at the conclusion of the Annual General Meeting in July 2020.  A search for Dr Hertzog's successor as Chairman will be initiated in due course and the Board will provide an update when available.

Desmond Smith, Senior Independent Director said:

"On behalf of the Board, I would like to thank Dr Hertzog for his commitment to Mediclinic throughout his 36 year tenure at management level and on the Board. Dr Hertzog has been instrumental in Mediclinic's growth from a domestic private hospital operator in South Africa to an international private healthcare services group. The Board and I wish Dr Hertzog well in his planned retirement."

Dr Edwin Hertzog, Chairman of Mediclinic, commented:

"Following my many years at Mediclinic, the time has come for me to retire as Chairman. During my time at Mediclinic, I have thoroughly enjoyed working with many talented people who have helped to grow an international business that puts patients first, providing world-class care.  I have great confidence that the team, Mediclinic's solid positioning and the efficient functioning of the Company will ensure an attractive future for all its stakeholders".

About Mediclinic International plc

Mediclinic is an international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates.

The Group's core purpose is to enhance the quality of life by way of appropriate healthcare services.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

Mediclinic comprises 77 hospitals, five sub-acute hospitals, 13 day case clinics and 21 outpatient clinics. Hirslanden operates 18 hospitals, two day case clinics and three outpatient clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operates 52 hospitals, five sub-acute hospitals and 9 day case clinics with more than 8 500 inpatient beds; and Mediclinic Middle East operates seven hospitals, two day case clinics and 21 outpatient clinics with more than 900 inpatient beds in the United Arab Emirates.

The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited

Jayne Meacham / Caroline Emmet

[phone]

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

[e-mail]

[phone]

Media queries

FTI Consulting

Brett Pollard/Debbie Scott - UK

[phone]

Sherryn Schooling - South Africa

[phone]

Registered address: 6^th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE Ltd sponsor: Rand Merchant Bank (A division of FirstRand Bank Ltd)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

 

END

 

 

BOAPGUWCMUPBGWC